高斯过程用于儿科药物剂量方案资格验证
药物开发常先研究成人再研究儿科人群,儿科试验剂量多由成人药代动力学模型按体型缩放外推。本文提出基于高斯过程(GP)的非参数回归模型,检测外推假设的偏离,并与成人模型的参数扩展比较。模拟和临床研究数据示例显示,GP方法能从稀疏儿科数据中可靠检测成熟趋势。
要点
- 儿科剂量外推假设儿童仅为缩小版成人,可能忽略器官成熟等额外效应。
- 高斯过程模型可检测外推假设的偏离,并与参数扩展方法比较。
- 模拟和临床数据示例表明GP方法能从稀疏儿科数据可靠检测成熟趋势。
核心结论
- 高斯过程方法能从稀疏儿科数据中可靠检测成熟趋势,用于验证外推假设。
研究设计与样本
- 提出基于高斯过程的非参数回归模型,并与成人模型的参数扩展比较,包括模拟和临床研究数据示例。
主要发现
- GP方法能从稀疏儿科数据中可靠检测成熟趋势。
临床怎么用
- 在获得儿科试验数据后,可用GP模型检测外推假设偏离,辅助儿科剂量方案资格验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug development commonly studies an adult population first and then the pediatric population. The knowledge from the adult population is taken advantage of for the design of the pediatric trials. Adjusted drug doses for these are often derived from adult pharmacokinetic (PK) models which are extrapolated to patients with smaller body size. This extrapolation is based on scaling physiologic model parameters with a body size measure accounting for organ size differences. The inherent assumption is that children are merely small adults. However, children can be subject to additional effects such as organ maturation. These effects are not present in the adult population and are possibly overlooked at the design stage of the pediatric trials. It is thus crucial to qualify the extrapolation assumptions once the pediatric trial data are available. In this work, we propose a model based on a non-parametric regression method called Gaussian process (GP) to detect deviations from the made extrapolation assumptions. We introduce the theoretical background of this model and compare its performance to a parametric expansion of the adult model. The comparison includes simulations and a clinical study data example. The results show that the GP approach can reliably detect maturation trends from sparse pediatric data.
引用
- Siivola E, Weber S, Vehtari A, et al. Qualifying drug dosing regimens in pediatrics using Gaussian processes. Stat Med. 2021. PMID: 33586203. doi:10.1002/sim.8907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。